Previous studies using glioma stem cell lines demonstrated that glioma stem cells were highly sensitive to novel inhibitors of MDM2, such as AMG232 and BI-907828 [51,52], which was consistent with the present study conducted by inhibiting MDM2 both genetically and pharmacologically using RG7112. This evidence concerns the gene MDM2 and central nervous system cancer.